318,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

This updated edition is a comprehensive treatise that spans the complete range of basic biochemistry of bone and cartilage components to the clinical evaluation of disease markers in bone and joint disorders. With contributions from over 75 international experts, this latest edition is indispensable reading for those involved in skeletal research as well as for rheumatologists, endocrinologists, clinical biochemists, and other clinical disciplines participating in the management of patients with bone and cartilage diseases. *Part I provides an up-to-date account of current knowledge of the…mehr

Produktbeschreibung
This updated edition is a comprehensive treatise that spans the complete range of basic biochemistry of bone and cartilage components to the clinical evaluation of disease markers in bone and joint disorders. With contributions from over 75 international experts, this latest edition is indispensable reading for those involved in skeletal research as well as for rheumatologists, endocrinologists, clinical biochemists, and other clinical disciplines participating in the management of patients with bone and cartilage diseases. *Part I provides an up-to-date account of current knowledge of the structure, biosynthesis and molecular biology of the major tissue components*Part II covers the organizational structure and cellular metabolism of bone and cartilage*Part III deals with the utility of components specific to bone and cartilage as biomarkers of health and disease
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Markus J. Seibel completed a medical degree and a doctoral degree in 1984 from the University of Mainz, Germany and the University of Pennsylvania, Philadelphia. Since 1996, he has been the head of the Endocrine Laboratories at Heidelberg University, Germany and a consultant in Endocrinology. Since 1997, he has been an Associate Professor and Member of the Faculty of Medicine at the University of Heidelberg and as of 1999, he will be Associate to the Director of the Department of Endocrinology and Metabolism. His research interests include bone and cartilage metabolism, treatment of osteoporosis, and thyroid carcinoma.
Dr. Bilezikian, Professor of Medicine and Pharmacology at the College of Physicians and Surgeons, Columbia University is the Chief of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia-Presbyterian Medical Center. He also serves as Associate Chair, Department of Medicine.
Dr. Bilezikian received his undergraduate training at Harvard College and his medical training at the College of Physicians and Surgeons. He completed four years of house staff training (internship and residency) including the Chief Medical Residency of the Medical Service at Columbia Presbyterian Medical Center. Dr. Bilezikian received his training in Metabolic Bone Diseases and in Endocrinology at the NIH where he served as a Clinical Associate in the Mineral Metabolism Branch under the tutelage of Dr. Gerald Aurbach.
Dr. Bilezikian belongs to a number of professional societies, including the American Society for Bone and Mineral Research, of which he served as President in 1996. He is a member of the Endocrine Society, the American Federation for Clinical Research, the American Society for Clinical Investigation, the Association of American Physicians, the American Association of Clinical Endocrinologists, the American Society for Pharmacology and Experimental Therapeutics, and the International Society of Clinical Densitometry, of which he is President.
He is Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism. His books include Editor-in-Chief of The Parathyroids (1994), and co-editor of Principles of Bone Biology (1996), The Aging Skeleton (1999), and Dynamics of Bone and Cartilage Metabolism (1999). He has been on numerous panels, including serving as Chair of the NIH Consensus Development Panel on Optimal Calcium Intake, and the Food and Nutrition Board of the National Academy of Sciences. He is a major national and international spokesperson for the field of metabolic bone diseases. Dr. Bilezikian's major research interests are related to the clinical investigation of metabolic bone diseases, particularly osteoporosis and primary hyperparathyroidism. His is the recipient of the Distinguished Physician Award of the Endocrine Society and of the Frederic C. Bartter Award of the American Society for Bone and Mineral Research for Excellence in the Clinical Research. He also has an active laboratory program in the biochemical mechanisms of the hormones that regulate calcium metabolism. His publications, which number of 350, speak to his active original investigative initiatives as well as his demand as an author of many reference sources of endocrinology and metabolic bone diseases.